Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

1 results
10:21 AM, Apr 13, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Abpro planning $69M NASDAQ listing

to develop it to treat HER2-positive solid tumors in Orphan indications. ABP-201 targets VEGF and angiopoietin 2
ANG2; ANPT2). The company intends to develop that antibody to treat vascular diseases of the eye …